Journal
TRANSFUSION MEDICINE REVIEWS
Volume 29, Issue 2, Pages 102-109Publisher
W B SAUNDERS CO-ELSEVIER INC
DOI: 10.1016/j.tmrv.2014.09.006
Keywords
t-PA; Plasmin; Fibrinolysis; Tranexamic acid; Plasminogen activation
Categories
Funding
- National Health and Medical Research Foundation of Australia [1045755, 1045756]
- Australian Post Graduate Scholarship
Ask authors/readers for more resources
The fibrinolytic system, known for its ability to regulate the activation of the zymogen plasminogen into active plasmin, has been primarily associated with the removal of fibrin and blood clots. Tissue-type plasminogen activator, the most well-recognized plasminogen activator, was harnessed for therapeutic benefit against thromboembolic disorders more than 30 years ago, whereas inhibition of this system has been proven effective for certain bleeding disorders. However, in recent years, new and unexpected functional roles for this system have been identified mostly in relation to the central nervous system that are both unrelated and independent of fibrin degradation and clot removal. Hence, it seems reasonable to ask whether agents used to modify components or activities of the fibrinolytic system have any clinical consequences unrelated to their intended use in hemostasis. This review will provide an overview of these new features of the fibrinolytic system and will also focus on prospective considerations in the use of fibrinolytic and antifibrinolytic agents. (C) 2015 Elsevier Inc. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available